IDSA coordinated a letter,
joined by 47 other health groups, to President-elect Trump urging that federal
efforts to combat antimicrobial resistance be maintained in the years ahead.
Hughes, The Journal of the American Medical Association vol. 305 no. February 22, 2011 1027-1028.
A commentary in JAMA by IDSA President James Hughes, MD, FIDSA (subscription required).
IDSA, Clinical Infectious Diseases vol. 50 no. 8 April 15, 2010 1081-1083.
IDSA and other organizations call for a global commitment to develop 10 new systemic antibiotics by 2020.
Boucher et al., Clinical Infectious Diseases vol. 48 no. 1 January 1, 2009
IDSA expresses concern about the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens.
Spellberg et al., Clinical Infectious Diseases vol. 46 no. 2 January 15, 2008 155-164.
A call to action for the medical community from the Infectious Diseases Society of America.
Talbot et al., Clinical Infectious Diseases vol. 42 no. 5 March 1, 2006.
An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America